Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Sulfacetamide

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Sulfacetamide

    ACTIVE PHARMA INGREDIENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 90Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enforcement Report - Week of July 5, 2017
    Enforcement Report - Week of July 5, 2017

    05 Jul 2017

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-5-2017-1499230453.pdf

    FDA
    05 Jul 2017
    Share Share
    Enforcement Report - Week of March 22, 2017
    Enforcement Report - Week of March 22, 2017

    22 Mar 2017

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-22-2017-1490161550.pdf

    FDA
    22 Mar 2017
    Share Share
    US FDA Enforcement Report- 8/June/2016
    US FDA Enforcement Report- 8/June/2016

    08 Jun 2016

    // FDA

    https://www.pharmacompass.com/pdf/news/us-fda-enforcement-report-8june2016-1465388450.pdf

    FDA
    08 Jun 2016
    Share Share